Norman Z. Lai

Norman Z. Lai, Ph.D. joined Ibex Biosciences in 2016. For over 20 years, Dr. Lai has held several positions in academia, science and in the biotechnology industry. His work has focused on the development of recombinant viral gene vectors and the establishment of cell-based in vitro and in vivo assays resulting in new research technologies for the treatment of neurological metabolic disorders, autoimmune diseases, and early human cancer detection.

His early research includes gene therapy delivery effectiveness, in collaboration with Dr. Roscoe O. Brady, an international leader in the field of metabolic and enzyme replacement therapy at the National Institute of Nonlogical Disorders and Strokes (NINDS), National Institutes of Health (NIH), and as Executive Director of Research and Development at U.S. Precision System Science Inc., where he worked on new diagnostic platforms for detecting single nucleotide polymorphisms (SNP) mutations sites of genetic metabolic disorders.

Dr. Lai received a Ph.D. in Pharmaceutical Bioscience and a Master of Science in Pharmacy from the University of Uppsala Sweden. He was a Postdoctoral Research Fellow at the Department of Medical and Molecular Genetics at Indiana University School of Medicine and an outstanding Research Fellow at Developmental and Metabolic Neurology Branch, NINDS, NIH. He also serves on the Board of Directors of US MediGene Inc, and serves as Vice Chairman of the Scientific Advisory Board Rafagen Inc. He is the co-author of numerous scientific publications and is the co-inventor of many patents and patent applications.